Semi-preparative chromatographic purification of the enantiomers S-(-)-amlodipine and R-(+)-amlodipine

被引:31
作者
Luksa, J
Josic, D
Podobnik, B
Furlan, B
Kremser, M
机构
[1] OCTAPHARMA PHARMAZEUT PRODUKTIONSGES MBH,A-1100 VIENNA,AUSTRIA
[2] LEK PHARMACEUT & CHEM CO DD,LJUBLJANA 1526,SLOVENIA
来源
JOURNAL OF CHROMATOGRAPHY B | 1997年 / 693卷 / 02期
关键词
enantiomer separation; amlodipine;
D O I
10.1016/S0378-4347(97)00069-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Pharmacokinetic studies of optically pure compounds after single enantiomer administration are becoming increasingly important. The process of racemization in vivo can diminish all expected advantages of single enantiomer treatment. Amlodipine, one of the calcium channel blockers, currently used in therapy as a racemate, is one of such drugs under study. In order to administer single enantiomers of amlodipine to healthy volunteers both were chromatographically purified and characterised. The two optical isomers of amlodipine, active S-(-)- and non-active R-(+)-amlodipine, were purified using chromatographic procedure adopted from the analytical separation. Enantiomers were successfully converted to benzenesulphonic salt without any racemization. All semi-preparative purifications were monitored with complementary analytical methods, HPLC and CE, along with the determination of optical activity so that the final product was sufficiently defined for further in vivo studies. The analytical method developed for the determination of plasma concentrations of each enantiomer of amlodipine in these studies is also briefly described.
引用
收藏
页码:367 / 375
页数:9
相关论文
共 14 条
[1]   An overview of the applications of capillary electrophoresis to the analysis of pharmaceutical raw materials and excipients [J].
Altria, KD ;
Elgey, J ;
Lockwood, P ;
Moore, D .
CHROMATOGRAPHIA, 1996, 42 (5-6) :332-342
[2]   QUANTITATIVE ASPECTS OF THE APPLICATION OF CAPILLARY ELECTROPHORESIS TO THE ANALYSIS OF PHARMACEUTICALS AND DRUG-RELATED IMPURITIES [J].
ALTRIA, KD .
JOURNAL OF CHROMATOGRAPHY, 1993, 646 (02) :245-257
[3]  
CALDWELL J, 1995, PHARM NEWS, V2, P22
[4]  
FDA (Food and Drug Administration), 1992, FED REG, V57
[5]  
FLYKT E, 1994, ISCD 94 STOCKH
[6]  
Gattuso M.J., 1996, PHARM TECH EUROPE, V8, P20
[7]   DETERMINATION OF THE ABSOLUTE-CONFIGURATION OF THE ACTIVE AMLODIPINE ENANTIOMER AS (-)-S - A CORRECTION [J].
GOLDMANN, S ;
STOLTEFUSS, J ;
BORN, L .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (18) :3341-3344
[8]  
HEYDORN WE, 1995, PHARM NEWS, V2, P19
[9]   CLINICAL PHARMACOKINETICS OF CALCIUM-ANTAGONISTS - AN UPDATE [J].
KELLY, JG ;
OMALLEY, K .
CLINICAL PHARMACOKINETICS, 1992, 22 (06) :416-433
[10]  
RICH BR, 1995, SIGHT SOUND, V5, P20